News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.
Increased incidental detection of clonal hematopoiesis and new considerations for mutations in myelodysplastic precursors herald improved precision medicine strategies.
The Temple City, California-based firm has raised its full-year guidance for the third time this year and now expects 2020 revenues of $300 million.
The company presented new evidence for the sensitivity of its multi-cancer early detection test and robustness of its automated library prep system.
The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.
As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.
